SNAPSHOT: Nanomedicine at BioDelivery Sciences International

Company:	BioDelivery Sciences International	Website:	www.biodeliverysciences.com/
Contact:	Al Medwar, 919-582-9050 Vice President, Marketing and Corporate Development	Phone:	919-582-9050
E-mail:	[email protected]	Address:	801 Corporate Center Drive, Suite 210 Raleigh, NC 27607
Category:	Nanomedicine	Public Company:	Nasdaq: BDSI

Company Overview

BioDelivery Sciences is a specialty pharmaceutical company that is using patented drug delivery techniques to develop new uses of existing drugs.

Nanomedicine Related Products

Oral drug delivery of drugs encapsulated in a nanocrystalline structure called a nanocochleate. Their technique for encapsulating and protecting a drug is called Bioral®. Their first product using this technique is Bioral™ Amphotericin B, a drug used for treating systemic fungal diseases. Initial results of the phase 1 clinical study of Bioral™ Amphotericin B are available here.

Research Affiliations

"The Bioral® drug delivery technology was developed in collaboration with the University of Albany and the University of New Jersey Medical and Dental School, each of which has granted BioDelivery Sciences exclusive worldwide licenses under applicable patents."

Product Development Affiliations

BioDelivery Sciences is collabrating with Drugs for Neglected Diseases initiative (DNDi) to assess the efficacy and safety of Bioral™ Amphotericin B for the treatment of neglected diseases like leishmaniasis and Chagas disease.

BioDelivery Sciences has received a $1.3 million grant from the Walter Reed Army Institute of Research to study the use of Bioral Amphotericin B in the treatment of Cutaneous Leishmaniasis.

Subsidiaries or Parent Company

N/A

Primary Investors or Funding Source

Public company